In the wake of the Theranos implosion, many companies have approached diagnostic testing, especially from small blood samples, with great trepidation. And yet, where others have been treading lightly, Quanterix has been unabashedly marching forward, to put better diagnostics tools in the hands of scientists and clinical researchers. As a company, Quanterix’s fundamental goal is digitizing biomarker analysis to advance the science of precision health. They are achieving this goal by offering a wide array of products and services. However, in this podcast, we speak with Quanterix’s CEO, Kevin Hrusovsky about something a bit more principled: why he believes they are the “Anti-Theranos.” Take a listen:


Kevin Hrusovsky
President, Chairman, and CEO

Podcast Sponsored By:

Previous articleRemoving Anthrax Bacterial Armor May Lead to New Therapies
Next article27-Year-Old Suspect Charged in Murder of Max Planck Institute Scientist